HEXA and Tay-Sachs disease: Finally, positive preclinical results with HexA gene therapy in SD cat and mouse models and TSD model sheep, including reduction of GM2 accumulation, correction of cellular pathology, and slowing of neurological manifestations, were obtained when treatment was initiated prior to signs of significant neurodegeneration [5, 8–10].